RATIONALE: Nicotine improves the deficiencies of sensory gating function in schizophrenic patients and in dilute brown non-Agouti (DBA/2) mice. This effect of nicotine has been attributed to activation of the alpha7 nicotinic acetylcholine receptor (nAChR) subtype. OBJECTIVE: The aim of this study was to determine whether the activation of another nAChR subtype, the central nervous system (CNS) prominent alpha4beta2 receptor, also contributes to the effects of nicotine on sensory gating in DBA/2 mice. METHODS: Unanesthetized DBA/2 mice were treated either with nicotine, the alpha4beta2 antagonist dihydro-beta-erythroidine, the noncompetitive nAChR antagonist mecamylamine, or a combination of an antagonist and nicotine. Thereafter, gating was assessed by recording hippocampal evoked potentials (EP), which were elicited by pairs of auditory clicks. The EP response to the second click, or test amplitude (TAMP), was divided by the EP response to the first click, or condition amplitude (CAMP), to derive gating T:C ratios. RESULTS: Nicotine significantly (p<0.05) lowered T:C ratios by 42%, while significantly increasing CAMP by 55%. After a pretreatment with dihydro-beta-erythroidine, nicotine still significantly lowered T:C ratios by 28%; however, the nicotine-induced increase of CAMP was blocked. Mecamylamine blocked the effect of nicotine on both T:C ratios and CAMP. CONCLUSIONS: Activation of alpha4beta2 receptors by nicotine increases CAMP. However, under conditions where alpha4beta2 receptors are blocked, nicotine still lowers T:C ratios and may improve sensory gating, possibly through the activation of other nAChR subtypes such as alpha7. These effects of nicotine on auditory EPs may be indicative of a profile that would improve information processing in schizophrenia and other CNS diseases.
RATIONALE: Nicotine improves the deficiencies of sensory gating function in schizophrenicpatients and in dilute brown non-Agouti (DBA/2) mice. This effect of nicotine has been attributed to activation of the alpha7 nicotinic acetylcholine receptor (nAChR) subtype. OBJECTIVE: The aim of this study was to determine whether the activation of another nAChR subtype, the central nervous system (CNS) prominent alpha4beta2 receptor, also contributes to the effects of nicotine on sensory gating in DBA/2mice. METHODS: Unanesthetized DBA/2mice were treated either with nicotine, the alpha4beta2 antagonist dihydro-beta-erythroidine, the noncompetitive nAChR antagonist mecamylamine, or a combination of an antagonist and nicotine. Thereafter, gating was assessed by recording hippocampal evoked potentials (EP), which were elicited by pairs of auditory clicks. The EP response to the second click, or test amplitude (TAMP), was divided by the EP response to the first click, or condition amplitude (CAMP), to derive gating T:C ratios. RESULTS:Nicotine significantly (p<0.05) lowered T:C ratios by 42%, while significantly increasing CAMP by 55%. After a pretreatment with dihydro-beta-erythroidine, nicotine still significantly lowered T:C ratios by 28%; however, the nicotine-induced increase of CAMP was blocked. Mecamylamine blocked the effect of nicotine on both T:C ratios and CAMP. CONCLUSIONS: Activation of alpha4beta2 receptors by nicotine increases CAMP. However, under conditions where alpha4beta2 receptors are blocked, nicotine still lowers T:C ratios and may improve sensory gating, possibly through the activation of other nAChR subtypes such as alpha7. These effects of nicotine on auditory EPs may be indicative of a profile that would improve information processing in schizophrenia and other CNS diseases.
Authors: J P Sullivan; D Donnelly-Roberts; C A Briggs; D J Anderson; M Gopalakrishnan; M Piattoni-Kaplan; J E Campbell; D G McKenna; E Molinari; A M Hettinger; D S Garvey; J T Wasicak; M W Holladay; M Williams; S P Arneric Journal: Neuropharmacology Date: 1996-06 Impact factor: 5.250
Authors: S Leonard; C Breese; C Adams; K Benhammou; J Gault; K Stevens; M Lee; L Adler; A Olincy; R Ross; R Freedman Journal: Eur J Pharmacol Date: 2000-03-30 Impact factor: 4.432
Authors: Stanley Zammit; Peter Allebeck; Christina Dalman; Ingvar Lundberg; Tomas Hemmingsson; Glyn Lewis Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112
Authors: Karin R Tietje; David J Anderson; R Scott Bitner; Eric A Blomme; Paul J Brackemeyer; Clark A Briggs; Kaitlin E Browman; Dagmar Bury; Peter Curzon; Karla U Drescher; Jennifer M Frost; Ryan M Fryer; Gerard B Fox; Jens Halvard Gronlien; Monika Håkerud; Earl J Gubbins; Sabine Halm; Richard Harris; Rosalind J Helfrich; Kathy L Kohlhaas; Devalina Law; John Malysz; Kennan C Marsh; Ruth L Martin; Michael D Meyer; Angela L Molesky; Arthur L Nikkel; Stephani Otte; Liping Pan; Pamela S Puttfarcken; Richard J Radek; Holly M Robb; Eva Spies; Kirsten Thorin-Hagene; Jeffrey F Waring; Hilde Ween; Hongyu Xu; Murali Gopalakrishnan; William H Bunnelle Journal: CNS Neurosci Ther Date: 2008 Impact factor: 5.243
Authors: Karen E Stevens; Brandon Cornejo; Catherine E Adams; Lijun Zheng; Joan Yonchek; Keith L Hoffman; Uwe Christians; William R Kem Journal: Brain Res Date: 2010-07-03 Impact factor: 3.252
Authors: Noam D Rudnick; Andrew A Strasser; Jennifer M Phillips; Christopher Jepson; Freda Patterson; Joseph M Frey; Bruce I Turetsky; Caryn Lerman; Steven J Siegel Journal: Nicotine Tob Res Date: 2010-04-15 Impact factor: 4.244